MissionIR Articles
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has entered into legally binding investment agreements with nine institutional and individual…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Ranked No. 1 Globally in Multi-Cancer Screening and Detection Test Volume
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that Frost & Sullivan Company, a leading and well-known U.S. market analysis and research firm, has ranked AnPac…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Proprietary Medical Device Passes Registration Tests, Slated to Start Clinical Trial
AnPac Bio-Medical Science (NASDAQ: ANPC), a U.S.- and China-based biotechnology company focused on early cancer screening and detection, announced that its Class III medical device for lung cancer auxiliary diagnosis has passed stringent and rigorous…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Publication of Technical Paper on Biophysics-Based CDA Cancer Detection Technology
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its joint technical paper on novel Cancer Differentiation Analysis (“CDA”) Technology for multi-cancer screening with multiple leading…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial, Operations Report for Latest Period
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reported its unaudited financial results and business highlights for the nine…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Uniquely Positioned in Cancer Screening, Detection Market
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is the company behind a proprietary novel technology for early cancer screening and detection — the Cancer Differentiation Analysis (“CDA”).…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Issues Update on Underwritten Public Offering of American Depositary Shares
AnPac Bio (NASDAQ: ANPC) today issued a correction to its press release dated Nov. 9, 2021, regarding the pricing of its underwritten public offering of American Depositary Shares (“ADSs”). According to the update, the original release…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Begin Proposed Public Offering
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced that it is starting an underwritten public offering; the offering is…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Participate in Q4 Virtual Investor Summit
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov.…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging CDA Technology for Critical Early Cancer Detection
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, since 2015 has commercially proven out its concepts through the development and sale of its cancer detection technology, Cancer Differentiation…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses…
-
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection
Blood and genomic testing are becoming preferable means of early cancer screening and detection Leaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and Guardant AnPac Bio-Medical’s testing features a database…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reached a significant milestone and positive result in its general-population, cancer-risk…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released it unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Appoints New Executives, Promotes Team Members
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has named two new executive team members. The company has named Dr. Amir Inamdar as the chief medical officer for its European…
-
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leading the Way in Early Cancer Detection Space
Up to 50% of cancer is preventable, while other types can be detected or treated early, often resulting in complete remission for patients AnPac Bio-Medical Science Co., Ltd. uses blood-based testing to detect many types…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CDA Technology Detects Risk of Over 25 Different Cancer Types
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven…
-
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives College of American Pathologists Accreditation for U.S. Laboratory
AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021 Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging Partnerships to Save Patients’ Lives, Broaden Product Pipeline
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, recently announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holdings AG, to explore novel medical solutions.…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial